| Literature DB >> 29599298 |
Ioannis Arsenakis1, Filip Boyen2, Freddy Haesebrouck2, Dominiek G D Maes1.
Abstract
This study was conducted in a commercial 1000-sow herd facing recurrent exudative epidermitis (EE) outbreaks during the nursery period and assessed the efficacy of autogenous vaccination in controlling such outbreaks. The vaccine was produced using three Staphylococcus hyicus isolates recovered from affected pigs shortly before the onset of the study. All of those isolates were positive for the exhB gene, which encodes the exfoliative toxin type B (ExhB). From four consecutive farrowing batches of sows, two batches were vaccinated (V) against S hyicus at five and two weeks before farrowing, and two sow batches remained non-vaccinated (NV). Vaccination efficacy was primarily determined by the levels of metaphylactic antimicrobial usage, and the morbidity and mortality data for the pigs of the V and NV sows. The total amount of antimicrobials used metaphylactically against EE in pigs among the V and NV farrowing batches was 39,600 and 88,550 mg, respectively. The used daily dose pig to animal daily dose pig ratio for the V and NV batches were 1.31 and 1.79, respectively (a ratio of 0.8 to 1.2 is indicative of correct dosing). The morbidity and mortality rates were V=6.50 and NV=14.36 (P=0.008), and V=2.59 and NV=5.02 (P=0.000), respectively. To conclude, autogenous vaccination of the sows with a vaccine based on exhB-positive S hyicus isolates reduced metaphylactic treatment with antimicrobials as well as the morbidity and mortality rates in weaned pigs compared with pigs from NV sow batches. © British Veterinary Association (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: autogenous vaccination; exudative epidermitis; field study; staphylococcus hyicus
Mesh:
Substances:
Year: 2018 PMID: 29599298 PMCID: PMC6047161 DOI: 10.1136/vr.104720
Source DB: PubMed Journal: Vet Rec ISSN: 0042-4900 Impact factor: 2.695
Herd description and health management practices
| Number of sows | 1000 |
| Breed of sows | Topigs 20 |
| Breed of boars for artificial insemination | Piétrain |
| Vaccination of sows | |
| Atrophic rhinitis | Rhiniseng (Hipra) four weeks before farrowing |
| | Suiseng (Hipra) three weeks before farrowing |
| PRRS(V) | Ingelvac PRRS MLV (Boehringer) eight weeks before farrowing |
| Swine influenza (type A) | Gripovac 3 (Merial) six weeks before farrowing |
| Vaccination of gilts in quarantine unit | |
| | Ingelvac MycoFLEX (Boehringer) upon entering the unit |
| Parvovirus | Parvosuin-MR (Hipra) two times four weeks apart |
| PCV2 | Ingelvac CircoFLEX (Boehringer) two times three weeks apart |
| PRRS(V) | Ingelvac PRRS MLV (Boehringer) once four weeks before breeding |
| Swine influenza (type A) | Gripovac 3 (Merial) two times three weeks apart |
| Medication of suckling pigs | Iron (Prolongal 200, Bayer) on day 3 |
| Vaccination in the nursery unit (days 21–70) | |
| PRRS(V) | Ingelvac PRRS MLV (Boehringer) on day 23 |
| Medication in the nursery unit (days 21–70), before the initiation of the study | In-feed apramycin (Apralan, Elanco) after weaning for 14 days |
PCV2, porcine circovirus type 2; PRRS(V), porcine reproductive and respiratory syndrome virus.
Antimicrobial susceptibility profiles for Staphylococcus hyicus isolates from non-treated pigs with clinical signs of exudative epidermitis, before the initiation (n=9) and during the study (n=16)
| Number (%) of resistant | ||
| Antimicrobials tested | Before the study | During the study |
| Ampicillin | 2/9 | 2/16 |
| Cephalexin | 0/9 | 0/16 |
| Cefquinome | 0/9 | 0/16 |
| Ceftiofur | 0/9 | 0/16 |
| Clindamycin | 9/9 | 3/16 |
| Doxycycline | 2/9 | 2/16 |
| Erythromycin | 3/9 | 2/16 |
| Florfenicol | 0/9 | 0/16 |
| Neomycin | 1/9 | 1/16 |
| Penicillin | 2/9 | 2/16 |
| Tetracycline | 2/9 | 3/16 |
| Sulphadiazine-trimethoprim | 2/9 | 1/16 |
| Tylosin | 0/9 | 0/16 |
Distribution of the weaned pigs that originated from the different farrowing batches (A–D) in each nursery unit
| Farrowing batch | N1 | N2 |
| A | Whole unit filled | 2 |
| B | No pigs placed | 4 |
| C | Whole unit filled | 2 |
| D | No pigs placed | 4 |
The total capacity of N1 was 960 pigs, while for N2 it was 3360 pigs. In N2 the numbers represent the number of compartments that were fully filled with pigs from each farrowing batch.
Per cent (number) of pigs with clinical signs of exudative epidermitis that received metaphylactic antimicrobial treatment (also representing morbidity rates)
| Nursery unit | NV | V | P value |
| Both units | 14.36 (523/3643)A | 6.50 (264/4061)B | 0.008 |
| N1 | 7.00 (255/3643) | n/a | n/a |
| N2 | 7.36 (268/3643) | 6.50 (264/4061) | 0.139 |
Rates were calculated according to the total number of animals included in the non-vaccinated (batches A and C) and vaccinated (batches B and D) farrowing batches upon transfer to the nursery units.
Vaccination status: NV (pigs originating from non-vaccinated sow farrowing batches) and V (pigs originating from vaccinated sow farrowing batches). Values with different superscripts within a row are significantly different (P<0.05).
n/a, non-applicable.
Per cent (number) of dead pigs with clinical signs of exudative epidermitis together with the total number of pigs that died from all causes
| Whole batch level/pigs with EE signs | Whole batch level/overall mortality | |||||
| Nursery unit | NV | V | P value | NV | V | P* value |
| Both units | 5.02 (183/3643)A | 2.59 (105/4061)B | 0.000 | 7.05 (257/3643)A | 3.94 (160/4061)B | 0.000 |
| N1 | 2.47 (90/3643) | n/a | n/a | 3.29 (120/3643) | n/a | n/a |
| N2 | 2.55 (93/3643) | 2.59 (105/4061) | 0.928 | 3.76 (137/3643) | 3.94 (160/4061) | 0.730 |
The contribution of each nursery unit (N1 and N2) on the combined (both units) mortality rates between three and ten weeks of age is presented separately. All mortality rates were calculated according to the total number of animals included in the non-vaccinated (NV; batches A and C) and vaccinated (V; batches B and D) farrowing batches upon transfer to the nursery units.
Vaccination status: NV (pigs originating from non-vaccinated sow farrowing batches) and V (pigs originating from vaccinated sow farrowing batches). Values with different superscripts within a row are significantly different (P<0.05 and P*<0.05). The P value refers to the comparisons between the summaries of the NV (A–C) and V (B–D) batches concerning the pigs that died showing signs of EE and the P* value to the comparisons between the summaries of the NV (A–C) and V (B–D) batches concerning the pigs that died from all causes.
n/a, non-applicable.
Performance parameters from three to ten weeks of age for the selected pigs originating from the non-vaccinated (NV; batches A and C) and vaccinated (V; batches B and D) farrowing batches (average±sd)
| Performance parameters† | Age (weeks) | A | B | C | D | P value | A–C (NV) | B–D (V) | P* value |
| n=180 | n=180 | n=180 | n=180 | n=360 | n=360 | ||||
| Average bodyweight (kg) | 3 | 5.03±1.12 | 5.46±1.09 | 5.12±1.08 | 5.50±1.16 | 0.673 | 5.09±1.10A | 5.48±1.13B | 0.000 |
| 10 | 23.91±4.24 | 25.81±4.42 | 24.18±4.45 | 24.71±4.84 | 0.051 | 24.07±4.36 | 25.15±4.70 | 0.643 | |
| Weight gain (kg) | 3–10 | 18.89±3.79 | 20.32±3.84 | 19.06±3.98 | 19.21±4.25 | 0.055 | 18.99±3.90 | 19.66±4.12 | 0.628 |
| ADG (g/pig/day) | 3–10 | 356±72 | 376±71 | 353±74 | 356±79 | 0.321 | 354±73 | 364±76 | 0.131 |
Data from batches A and C were summarised together, taking into account both nursery units (N1 and N2). Data from batches B and D were also summarised together (for N2).
Vaccination status: NV (pigs originating from non-vaccinated sow farrowing batches) and V (pigs originating from vaccinated sow farrowing batches). Values with different superscripts within a row are significantly different (P<0.05 and P*<0.05). The P value refers to the comparisons between the individual farrowing batches and the P* value to the comparisons between the summaries of the NV (A–C) and V (B–D) batches.
†Average daily gain (ADG).